Investigational Drug Information for RIST4721
✉ Email this page to a colleague
What is the development status for investigational drug RIST4721?
RIST4721 is an investigational drug.
There have been 6 clinical trials for RIST4721.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2022.
The most common disease conditions in clinical trials are Psoriasis, Brucellosis, and Hidradenitis Suppurativa. The leading clinical trial sponsors are Aristea Therapeutics, Inc. and [disabled in preview].
There are four US patents protecting this investigational drug and one hundred and seventeen international patents.
Summary for RIST4721
| US Patents | 4 |
| International Patents | 117 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2022-07-30) |
| Vendors | 11 |
Recent Clinical Trials for RIST4721
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) | Aristea Therapeutics, Inc. | Phase 2 |
| A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | Aristea Therapeutics, Inc. | Phase 2 |
| A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | Aristea Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for RIST4721
Top disease conditions for RIST4721
Top clinical trial sponsors for RIST4721
US Patents for RIST4721
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RIST4721 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| RIST4721 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| RIST4721 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| RIST4721 | ⤷ Try a Trial | Certain (25)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RIST4721
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RIST4721 | Argentina | AR099177 | 2034-01-24 | ⤷ Try a Trial |
| RIST4721 | Australia | AU2015208932 | 2034-01-24 | ⤷ Try a Trial |
| RIST4721 | Australia | AU2017200338 | 2034-01-24 | ⤷ Try a Trial |
| RIST4721 | Australia | AU2018202956 | 2034-01-24 | ⤷ Try a Trial |
| RIST4721 | Australia | AU2019202675 | 2034-01-24 | ⤷ Try a Trial |
| RIST4721 | Canada | CA2935625 | 2034-01-24 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
